ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions. To develop an evidence-based clinical practice guideline for the pharmacological treatment of peo...
Uloženo v:
| Vydáno v: | Multiple sclerosis Ročník 24; číslo 2; s. 96 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.02.2018
|
| Témata: | |
| ISSN: | 1477-0970, 1477-0970 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.
To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.
This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.
A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.
The present guideline will enable homogeneity of treatment decisions across Europe. |
|---|---|
| AbstractList | Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.
To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.
This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.
A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.
The present guideline will enable homogeneity of treatment decisions across Europe. Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.BACKGROUNDMultiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.OBJECTIVESTo develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.METHODSThis guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.RESULTSA total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.The present guideline will enable homogeneity of treatment decisions across Europe.CONCLUSIONThe present guideline will enable homogeneity of treatment decisions across Europe. |
| Author | Sormani, Maria Pia Hartung, Hans Peter Thompson, Alan J Lubetzki, Catherine Gold, Ralf Marcus, Elena Zipp, Frauke Siva, Axel Comi, Giancarlo Havrdova, Eva Clanet, Michel Miller, David H Thalheim, Christoph Fazekas, Franz Montalban, Xavier Chandraratna, Dhia Selmaj, Krysztof Derfuss, Tobias Kappos, Ludwig Liblau, Roland Sorensen, Per Soelberg Amato, Maria Pia Pilling, Steve Wiendl, Heinz Hemmer, Bernhard Olsson, Tomas Otero-Romero, Susana |
| Author_xml | – sequence: 1 givenname: Xavier surname: Montalban fullname: Montalban, Xavier organization: Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain – sequence: 2 givenname: Ralf surname: Gold fullname: Gold, Ralf organization: Department of Neurology, Ruhr University, St. Josef-Hospital, Bochum, Germany – sequence: 3 givenname: Alan J surname: Thompson fullname: Thompson, Alan J organization: Department of Brain Repair & Rehabilitation and Faculty of Brain Sciences, University College London Institute of Neurology, London, UK – sequence: 4 givenname: Susana surname: Otero-Romero fullname: Otero-Romero, Susana organization: Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain/Preventive Medicine and Epidemiology Department, Vall d'Hebron University Hospital, Barcelona, Spain – sequence: 5 givenname: Maria Pia surname: Amato fullname: Amato, Maria Pia organization: Department of Neurosciences, Psychology, Drugs and Child Health Area (NEUROFARBA), Section Neurosciences, University of Florence, Florence, Italy – sequence: 6 givenname: Dhia surname: Chandraratna fullname: Chandraratna, Dhia organization: Multiple Sclerosis International Federation, London, UK – sequence: 7 givenname: Michel surname: Clanet fullname: Clanet, Michel organization: Department of Neurology, Toulouse University Hospital, Toulouse, France – sequence: 8 givenname: Giancarlo surname: Comi fullname: Comi, Giancarlo organization: Neurological Department, Institute of Experimental Neurology (INSPE), Scientific Institute Hospital San Raffaele, Universita' Vita-Salute San Raffaele, Milan, Italy – sequence: 9 givenname: Tobias surname: Derfuss fullname: Derfuss, Tobias organization: Departments of Neurology and Biomedicine, University Hospital Basel, Basel, Switzerland – sequence: 10 givenname: Franz surname: Fazekas fullname: Fazekas, Franz organization: Department of Neurology, Medical University of Graz, Graz, Austria – sequence: 11 givenname: Hans Peter surname: Hartung fullname: Hartung, Hans Peter organization: Multiple Sclerosis Center, Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany – sequence: 12 givenname: Eva surname: Havrdova fullname: Havrdova, Eva organization: Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic – sequence: 13 givenname: Bernhard surname: Hemmer fullname: Hemmer, Bernhard organization: Department of Neurology, Klinikum Rechts der Isar, Technische Universität München and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany – sequence: 14 givenname: Ludwig surname: Kappos fullname: Kappos, Ludwig organization: University Hospital Basel, Basel, Switzerland – sequence: 15 givenname: Roland surname: Liblau fullname: Liblau, Roland organization: INSERM UMR U1043 - CNRS U5282, Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France – sequence: 16 givenname: Catherine surname: Lubetzki fullname: Lubetzki, Catherine organization: Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1127, ICM-GHU Pitié-Salpêtrière, Paris, France – sequence: 17 givenname: Elena surname: Marcus fullname: Marcus, Elena organization: Centre for Outcomes Research and Effectiveness (CORE), Research Department of Clinical, Educational and Health Psychology, University College London, London, UK – sequence: 18 givenname: David H surname: Miller fullname: Miller, David H organization: NMR Research Unit and Queen Square Multiple Sclerosis Centre, University College London Institute of Neurology, London, UK – sequence: 19 givenname: Tomas surname: Olsson fullname: Olsson, Tomas organization: Neuroimmunology Unit, Center for Molecular Medicine, Karolinska University Hospital Solna, Stockholm, Sweden – sequence: 20 givenname: Steve surname: Pilling fullname: Pilling, Steve organization: Centre for Outcomes Research and Effectiveness (CORE), Research Department of Clinical, Educational and Health Psychology, University College London, London, UK – sequence: 21 givenname: Krysztof surname: Selmaj fullname: Selmaj, Krysztof organization: Department of Neurology, Medical University of Lodz, Lodz, Poland – sequence: 22 givenname: Axel surname: Siva fullname: Siva, Axel organization: Clinical Neuroimmunology Unit and MS Clinic, Department of Neurology, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey – sequence: 23 givenname: Per Soelberg surname: Sorensen fullname: Sorensen, Per Soelberg organization: Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital, Rigshospitalet, Denmark – sequence: 24 givenname: Maria Pia surname: Sormani fullname: Sormani, Maria Pia organization: Biostatistics Unit, University of Genoa, Genoa, Italy – sequence: 25 givenname: Christoph surname: Thalheim fullname: Thalheim, Christoph organization: European Multiple Sclerosis Platform (EMSP), Schaerbeek, Belgium – sequence: 26 givenname: Heinz surname: Wiendl fullname: Wiendl, Heinz organization: Department of Neurology, University of Münster, Münster, Germany – sequence: 27 givenname: Frauke surname: Zipp fullname: Zipp, Frauke organization: Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunology (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29353550$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM9LwzAcxYNM3A-9e5IcvdQlabI0xzHmHEwFneCtpOk3rpI2tUkR_3srTvD03oMPj8ebolHjG0DokpIbSqWc01QwLjIxeEEJVydoQrmUCVGSjP75MZqG8E4IkTIVZ2jMVCpSIcgEva5X-6ft_fN8vXzAm74qwVUNYN_geADcHnRXa-Odf6uMdjh2oGMNTcTe4hZ86wB_VvGA697F6icF46DzoQrn6NRqF-DiqDP0crver-6S3eNmu1ruEjPsjonkmS2ZAKU5tYtCyNIqw4uMK1hYWjBRCp3yFKwighmlWWoLlRkGxCgmYcFm6Pq3t-38Rw8h5nUVDDinG_B9yKnKlBrOYmJAr45oX9RQ5m1X1br7yv_eYN8-gmMx |
| CitedBy_id | crossref_primary_10_1016_j_msard_2024_105547 crossref_primary_10_2217_nmt_2022_0031 crossref_primary_10_1177_17562864211001977 crossref_primary_10_7224_1537_2073_2021_062 crossref_primary_10_1016_j_msard_2022_103805 crossref_primary_10_1136_bmjopen_2019_029565 crossref_primary_10_1016_j_jemermed_2023_12_003 crossref_primary_10_1212_WNL_0000000000210049 crossref_primary_10_1007_s40120_024_00633_6 crossref_primary_10_1007_s41669_022_00381_z crossref_primary_10_1016_j_msard_2020_102158 crossref_primary_10_1177_1352458520984744 crossref_primary_10_1177_13524585241272938 crossref_primary_10_1002_ana_25746 crossref_primary_10_1016_j_msard_2020_102031 crossref_primary_10_1186_s13023_023_02789_0 crossref_primary_10_1016_j_heliyon_2023_e13350 crossref_primary_10_1186_s12883_023_03273_9 crossref_primary_10_26641_2307_0404_2020_2_206348 crossref_primary_10_1038_s41582_020_0383_x crossref_primary_10_1016_j_msard_2022_103915 crossref_primary_10_1007_s00415_019_09531_6 crossref_primary_10_1007_s10072_020_04434_1 crossref_primary_10_3389_fneur_2018_00835 crossref_primary_10_1016_j_msard_2020_102147 crossref_primary_10_1016_j_msard_2020_102146 crossref_primary_10_1212_NXI_0000000000200032 crossref_primary_10_1177_17562864231180734 crossref_primary_10_1146_annurev_bioeng_110122_014306 crossref_primary_10_1371_journal_pone_0222012 crossref_primary_10_1080_14656566_2019_1615880 crossref_primary_10_1186_s40035_024_00436_7 crossref_primary_10_1212_WNL_0000000000005574 crossref_primary_10_1007_s00415_024_12417_x crossref_primary_10_7224_1537_2073_2018_107 crossref_primary_10_1016_j_jns_2024_123052 crossref_primary_10_1007_s00415_020_09762_y crossref_primary_10_1177_1352458520924595 crossref_primary_10_1007_s40120_022_00422_z crossref_primary_10_1212_WNL_0000000000208051 crossref_primary_10_1097_WCO_0000000000000960 crossref_primary_10_1186_s12913_023_10099_1 crossref_primary_10_1016_j_neurad_2023_10_010 crossref_primary_10_1016_j_msard_2024_105435 crossref_primary_10_1016_j_neurol_2020_05_005 crossref_primary_10_1016_j_msard_2024_105676 crossref_primary_10_2217_nmt_2022_0002 crossref_primary_10_1007_s40120_022_00421_0 crossref_primary_10_1016_S1474_4422_20_30063_6 crossref_primary_10_1016_j_jval_2021_05_020 crossref_primary_10_1080_14737167_2021_1981134 crossref_primary_10_1080_03007995_2024_2339938 crossref_primary_10_1177_1352458520917936 crossref_primary_10_1177_2045894019872192 crossref_primary_10_1186_s12874_024_02264_9 crossref_primary_10_3390_ijms26104885 crossref_primary_10_1016_j_msard_2019_101406 crossref_primary_10_1016_j_msard_2019_101887 crossref_primary_10_1002_brb3_1598 crossref_primary_10_1016_j_msard_2022_103847 crossref_primary_10_1016_j_msard_2020_102354 crossref_primary_10_1016_j_msard_2023_105064 crossref_primary_10_1016_j_msard_2020_102591 crossref_primary_10_1007_s40265_020_01437_2 crossref_primary_10_1055_a_1268_8070 crossref_primary_10_3389_fimmu_2020_591563 crossref_primary_10_1007_s40120_023_00549_7 crossref_primary_10_1177_2055217320910778 crossref_primary_10_3389_fneur_2021_613769 crossref_primary_10_1007_s40263_018_0541_5 crossref_primary_10_3390_ctn6040027 crossref_primary_10_3389_fimmu_2021_661882 crossref_primary_10_1002_brb3_2679 crossref_primary_10_1007_s40258_019_00500_8 crossref_primary_10_1177_13524585211010128 crossref_primary_10_3389_fimmu_2025_1644278 crossref_primary_10_1177_1352458519854162 crossref_primary_10_1016_j_bulcan_2021_03_020 crossref_primary_10_1016_j_msard_2019_101891 crossref_primary_10_1136_jnnp_2019_321523 crossref_primary_10_1016_j_msard_2020_102461 crossref_primary_10_1177_1352458520981300 crossref_primary_10_1177_1756286418770378 crossref_primary_10_1016_j_msard_2023_105045 crossref_primary_10_3390_jcm10030463 crossref_primary_10_1212_NXI_0000000000000636 crossref_primary_10_3390_ph17080983 crossref_primary_10_1007_s00415_021_10836_8 crossref_primary_10_1177_1756286420935019 crossref_primary_10_1016_j_rehab_2021_101529 crossref_primary_10_1007_s00415_023_12137_8 crossref_primary_10_1016_j_ejrad_2023_111019 crossref_primary_10_1177_17562864221129383 crossref_primary_10_1186_s12883_020_01882_2 crossref_primary_10_2217_cer_2020_0122 crossref_primary_10_1080_14656566_2020_1763304 crossref_primary_10_3389_fneur_2018_00522 crossref_primary_10_1016_j_nrleng_2024_01_003 crossref_primary_10_1016_j_steroids_2019_04_006 crossref_primary_10_1177_17562864241241382 crossref_primary_10_3389_fneur_2025_1570566 crossref_primary_10_1007_s40263_022_00965_7 crossref_primary_10_1186_s12859_020_03823_9 crossref_primary_10_57264_cer_2022_0175 crossref_primary_10_1007_s10072_023_06876_9 crossref_primary_10_1016_j_msard_2020_102124 crossref_primary_10_1007_s40263_024_01117_9 crossref_primary_10_1007_s40267_023_01030_z crossref_primary_10_1007_s00415_022_11193_w crossref_primary_10_3390_jcm12062240 crossref_primary_10_1080_14737175_2018_1438190 crossref_primary_10_22379_anc_v41i1_1862 crossref_primary_10_1212_NXI_0000000000200420 crossref_primary_10_1007_s40263_018_0564_y crossref_primary_10_3389_fimmu_2022_852563 crossref_primary_10_2217_cer_2020_0267 crossref_primary_10_1016_j_autrev_2023_103449 crossref_primary_10_1186_s42466_024_00333_4 crossref_primary_10_1007_s40263_018_0562_0 crossref_primary_10_1001_jamanetworkopen_2024_6345 crossref_primary_10_1016_j_msard_2021_103012 crossref_primary_10_3389_fimmu_2023_1234869 crossref_primary_10_1007_s40120_021_00297_6 crossref_primary_10_1111_ene_16077 crossref_primary_10_1177_13524585241275471 crossref_primary_10_3389_fneur_2023_1112193 crossref_primary_10_1016_j_msard_2022_103759 crossref_primary_10_1177_17562864241284372 crossref_primary_10_1016_j_ctim_2020_102595 crossref_primary_10_1186_s12883_021_02483_3 crossref_primary_10_1177_2055217319833006 crossref_primary_10_1007_s40120_018_0112_1 crossref_primary_10_1002_eji_202250234 crossref_primary_10_1016_j_neurol_2020_03_008 crossref_primary_10_1007_s40120_024_00707_5 crossref_primary_10_3389_fimmu_2021_669811 crossref_primary_10_1038_s41582_022_00675_0 crossref_primary_10_1016_j_ab_2025_115781 crossref_primary_10_1177_13524585241295677 crossref_primary_10_3892_etm_2023_12067 crossref_primary_10_1007_s00415_024_12270_y crossref_primary_10_1007_s40120_020_00200_9 crossref_primary_10_3390_cells9010075 crossref_primary_10_1111_ene_13819 crossref_primary_10_1177_1352458518767323 crossref_primary_10_1007_s40120_022_00339_7 crossref_primary_10_1016_j_msard_2021_103278 crossref_primary_10_1007_s40265_019_01229_3 crossref_primary_10_1177_1179573519831997 crossref_primary_10_1007_s40120_024_00650_5 crossref_primary_10_1038_s41582_018_0082_z crossref_primary_10_1007_s11940_024_00814_6 crossref_primary_10_1155_2024_5383099 crossref_primary_10_1007_s40265_021_01650_7 crossref_primary_10_1177_17562864241229325 crossref_primary_10_1016_j_msard_2024_106159 crossref_primary_10_1007_s40265_022_01672_9 crossref_primary_10_1016_j_msard_2022_103684 crossref_primary_10_1016_j_msard_2022_103688 crossref_primary_10_1016_j_msard_2021_103326 crossref_primary_10_1186_s12883_020_01645_z crossref_primary_10_1177_2055217320959116 crossref_primary_10_1515_cclm_2025_0678 crossref_primary_10_1080_01616412_2021_1967680 crossref_primary_10_1038_s41582_019_0170_8 crossref_primary_10_1080_1744666X_2025_2522270 crossref_primary_10_1055_a_1824_6238 crossref_primary_10_1111_ene_14091 crossref_primary_10_2217_cer_2022_0193 crossref_primary_10_3389_fneur_2022_851413 crossref_primary_10_1007_s40263_019_00674_8 crossref_primary_10_1177_2284240319838524 crossref_primary_10_1111_ane_13301 crossref_primary_10_1177_2381468319855642 crossref_primary_10_1007_s00415_023_11969_8 crossref_primary_10_1097_WCO_0000000000000700 crossref_primary_10_1177_1352458519892555 crossref_primary_10_36290_neu_2022_054 crossref_primary_10_1136_ejhpharm_2018_001840 crossref_primary_10_1016_j_msard_2022_104406 crossref_primary_10_1016_S1474_4422_21_00364_1 crossref_primary_10_1016_j_msard_2019_02_010 crossref_primary_10_3390_medicina61040762 crossref_primary_10_1007_s40267_020_00809_8 crossref_primary_10_1016_j_nic_2024_03_002 crossref_primary_10_1080_01616412_2024_2377003 crossref_primary_10_1016_S0140_6736_18_30481_1 crossref_primary_10_1007_s41669_021_00282_7 crossref_primary_10_1016_j_autrev_2023_103358 crossref_primary_10_1016_j_msard_2025_106334 crossref_primary_10_1212_WNL_0000000000012224 crossref_primary_10_3390_ijms251910761 crossref_primary_10_1177_17562864241239117 crossref_primary_10_1259_bjr_20180926 crossref_primary_10_1007_s00120_023_02168_4 crossref_primary_10_3390_jcm11102807 crossref_primary_10_1016_j_msard_2019_03_022 crossref_primary_10_31083_j_fbl2911386 crossref_primary_10_1093_brain_awaa231 crossref_primary_10_1136_jnnp_2018_319208 crossref_primary_10_1016_j_msard_2025_106466 crossref_primary_10_1111_joim_13215 crossref_primary_10_1016_j_ibneur_2022_11_001 crossref_primary_10_3389_fimmu_2023_1290666 crossref_primary_10_1212_WNL_0000000000200549 crossref_primary_10_1016_j_msard_2023_104800 crossref_primary_10_1007_s40120_024_00589_7 crossref_primary_10_1177_17562864241285556 crossref_primary_10_3389_fimmu_2024_1446748 crossref_primary_10_1186_s13052_021_01025_4 crossref_primary_10_1136_bmjopen_2024_095952 crossref_primary_10_3889_oamjms_2022_9241 crossref_primary_10_3389_fneur_2022_844873 crossref_primary_10_2478_rrlm_2024_0019 crossref_primary_10_1186_s42466_019_0005_5 crossref_primary_10_1007_s11884_019_00525_8 crossref_primary_10_3390_ph15091077 crossref_primary_10_1007_s00415_025_13173_2 crossref_primary_10_1177_1756286420987031 crossref_primary_10_1186_s42466_025_00379_y crossref_primary_10_1007_s40263_020_00771_z crossref_primary_10_2217_nmt_2019_0024 crossref_primary_10_3390_medicina56020049 crossref_primary_10_1007_s40263_023_01036_1 crossref_primary_10_1177_1352458519840757 crossref_primary_10_1177_1756286420951072 crossref_primary_10_1080_14737167_2021_1945926 crossref_primary_10_1212_WNL_0000000000207664 crossref_primary_10_3390_jpm11101032 crossref_primary_10_1016_j_ncl_2023_06_004 crossref_primary_10_1371_journal_pone_0264328 crossref_primary_10_1212_WNL_0000000000010135 crossref_primary_10_1080_1744666X_2022_2031982 crossref_primary_10_1007_s00415_025_13283_x crossref_primary_10_1177_1352458518809326 crossref_primary_10_3390_nu13041198 crossref_primary_10_1177_13524585221116269 crossref_primary_10_3389_fneur_2023_1255496 crossref_primary_10_1177_13524585251349129 crossref_primary_10_1016_j_msard_2021_103091 crossref_primary_10_1186_s12883_020_01830_0 crossref_primary_10_2217_nmt_2020_0034 crossref_primary_10_1212_NXI_0000000000001006 crossref_primary_10_3389_fneur_2022_824926 crossref_primary_10_3389_fneur_2022_1035596 crossref_primary_10_1007_s12325_020_01349_3 crossref_primary_10_1177_17562864241252722 crossref_primary_10_1007_s00415_022_11341_2 crossref_primary_10_1016_j_bbmt_2019_02_014 crossref_primary_10_1007_s40120_021_00243_6 crossref_primary_10_1177_1756286420910310 crossref_primary_10_1177_13524585221139156 crossref_primary_10_1111_ene_15163 crossref_primary_10_1177_13524585241228426 crossref_primary_10_1177_11795735231195775 crossref_primary_10_1186_s12883_025_04095_7 crossref_primary_10_1177_17562864211039648 crossref_primary_10_1186_s12883_022_02986_7 crossref_primary_10_1007_s13760_024_02597_8 crossref_primary_10_1016_j_msard_2022_104422 crossref_primary_10_3389_fimmu_2021_799380 crossref_primary_10_1016_j_msard_2023_104729 crossref_primary_10_1007_s40265_023_01942_0 crossref_primary_10_1177_1756286420954119 crossref_primary_10_2217_nmt_2020_0054 crossref_primary_10_1016_S1474_4422_18_30248_5 crossref_primary_10_1177_17562864231183221 crossref_primary_10_1093_brain_awaa145 crossref_primary_10_1007_s11064_020_02960_0 crossref_primary_10_1016_j_jocn_2018_04_053 crossref_primary_10_2217_nmt_2020_0059 crossref_primary_10_3389_fneur_2023_1164001 crossref_primary_10_1177_17562864241233044 crossref_primary_10_1007_s00415_022_11408_0 crossref_primary_10_1016_j_msard_2022_104138 crossref_primary_10_3389_fneur_2021_651511 crossref_primary_10_1007_s12325_022_02250_x crossref_primary_10_1007_s40120_020_00201_8 crossref_primary_10_1016_j_heliyon_2024_e26173 crossref_primary_10_1016_j_yfrne_2018_07_001 crossref_primary_10_3390_cells14080606 crossref_primary_10_1016_j_msard_2025_106278 crossref_primary_10_1111_bcp_15071 crossref_primary_10_1177_1352458520985118 crossref_primary_10_1007_s40263_019_00671_x crossref_primary_10_1002_jgh3_12938 crossref_primary_10_1055_a_2540_1749 crossref_primary_10_1186_s13643_024_02677_z crossref_primary_10_1186_s42466_021_00139_8 crossref_primary_10_1111_ene_14259 crossref_primary_10_1177_17562864231198963 crossref_primary_10_1155_2019_7290285 crossref_primary_10_1186_s12874_020_0906_6 crossref_primary_10_1007_s40263_020_00716_6 crossref_primary_10_1016_j_msard_2019_04_003 crossref_primary_10_1177_1352458518801764 crossref_primary_10_1093_qjmed_hcaa348 crossref_primary_10_1177_13524585231161494 crossref_primary_10_7759_cureus_45454 crossref_primary_10_1016_j_msard_2021_103051 crossref_primary_10_1177_1352458519851212 crossref_primary_10_3390_ijms25126342 crossref_primary_10_1016_j_drudis_2020_11_022 crossref_primary_10_1002_brb3_70326 crossref_primary_10_1007_s00415_025_13293_9 crossref_primary_10_1055_s_0045_1809400 crossref_primary_10_36927_2079_0325_V30_is1_2022_16 crossref_primary_10_1371_journal_pone_0320069 crossref_primary_10_18553_jmcp_2025_31_8_a_s1 crossref_primary_10_1111_ene_15593 crossref_primary_10_1007_s40120_025_00726_w crossref_primary_10_1016_j_msard_2020_101956 crossref_primary_10_1177_20552173211001571 crossref_primary_10_20344_amp_22380 crossref_primary_10_2147_PPA_S284425 crossref_primary_10_1111_bcp_14198 crossref_primary_10_1371_journal_pone_0261050 crossref_primary_10_1016_j_msard_2021_103076 crossref_primary_10_1016_j_msard_2020_101948 crossref_primary_10_1177_1352458520952310 crossref_primary_10_1016_j_autrev_2018_09_012 crossref_primary_10_1038_s41572_018_0041_4 crossref_primary_10_3389_fimmu_2023_1004795 crossref_primary_10_1177_20552173221085741 crossref_primary_10_1177_20552173231201422 crossref_primary_10_1016_j_jbc_2022_102265 crossref_primary_10_1212_WNL_0000000000209752 crossref_primary_10_3390_cells8101280 crossref_primary_10_3390_ijms232314578 crossref_primary_10_7224_1537_2073_2023_079 crossref_primary_10_1007_s40263_021_00830_z crossref_primary_10_1016_j_heliyon_2024_e26658 crossref_primary_10_1177_20552173221150370 crossref_primary_10_1016_j_msard_2024_105829 crossref_primary_10_1111_ene_14324 crossref_primary_10_1016_j_jns_2019_03_030 crossref_primary_10_1177_20406223211063032 crossref_primary_10_1016_j_msard_2020_102435 crossref_primary_10_1016_j_msard_2020_102433 crossref_primary_10_1016_j_msard_2020_102554 crossref_primary_10_3389_fneur_2022_904757 crossref_primary_10_1016_j_acra_2020_08_006 crossref_primary_10_1080_14737175_2025_2508777 crossref_primary_10_1007_s40261_019_00750_3 crossref_primary_10_1177_2381468319879134 crossref_primary_10_1111_ene_15422 crossref_primary_10_1186_s12883_022_02809_9 crossref_primary_10_1177_1352458519898340 crossref_primary_10_1177_20420986221143830 crossref_primary_10_3389_fneur_2025_1557947 crossref_primary_10_1016_S1474_4422_19_30151_6 crossref_primary_10_1016_S1634_7072_24_49343_4 crossref_primary_10_1080_17512433_2024_2410393 crossref_primary_10_1016_j_msard_2019_101452 crossref_primary_10_1186_s12883_023_03184_9 crossref_primary_10_1212_CPJ_0000000000001118 crossref_primary_10_1093_brain_awad278 crossref_primary_10_1097_01_NT_0000978660_43389_1e crossref_primary_10_4103_abr_abr_376_23 crossref_primary_10_1038_s41577_023_00902_9 crossref_primary_10_1007_s40263_024_01074_3 crossref_primary_10_1080_21556660_2020_1721507 crossref_primary_10_11604_pamj_2024_49_16_38051 crossref_primary_10_1177_13524585221083194 crossref_primary_10_1159_000514432 crossref_primary_10_1177_13524585241302170 crossref_primary_10_1177_20552173251317020 crossref_primary_10_3390_biomedicines10082041 crossref_primary_10_5507_bp_2023_023 crossref_primary_10_3390_ijms23095162 crossref_primary_10_1111_cts_13492 crossref_primary_10_3389_fneur_2021_708723 crossref_primary_10_1007_s40120_019_0141_4 crossref_primary_10_1177_13524585251335466 crossref_primary_10_1007_s00415_019_09395_w crossref_primary_10_1016_j_msard_2021_102747 crossref_primary_10_1007_s40120_022_00430_z crossref_primary_10_1016_j_nerep_2025_100260 crossref_primary_10_1186_s12883_021_02347_w crossref_primary_10_1016_j_ejphar_2022_175185 crossref_primary_10_1016_j_msard_2018_11_033 crossref_primary_10_11124_JBISRIR_D_19_00178 crossref_primary_10_1186_s13063_021_05726_3 crossref_primary_10_1212_WNL_0000000000008319 crossref_primary_10_1177_1352458520911174 crossref_primary_10_1177_1756286420936165 crossref_primary_10_1016_j_neurol_2020_07_001 crossref_primary_10_3389_fnins_2025_1579511 crossref_primary_10_2147_PPA_S245955 crossref_primary_10_1016_j_msard_2023_105345 crossref_primary_10_1016_S0140_6736_23_01473_3 crossref_primary_10_1371_journal_pone_0231722 crossref_primary_10_1136_bmjopen_2021_051509 crossref_primary_10_1136_jnnp_2024_335495 crossref_primary_10_1186_s12974_019_1593_2 crossref_primary_10_1080_00325481_2020_1734394 crossref_primary_10_1089_biores_2020_0004 crossref_primary_10_1177_17562864211019574 crossref_primary_10_1007_s40272_019_00338_6 crossref_primary_10_1007_s00415_021_10673_9 crossref_primary_10_1177_2055217320959802 crossref_primary_10_36290_neu_2019_130 crossref_primary_10_1016_j_neurol_2022_09_006 crossref_primary_10_1016_j_msard_2020_102503 crossref_primary_10_3390_jcm13010214 crossref_primary_10_1007_s00415_025_13321_8 crossref_primary_10_1016_j_neurol_2020_06_020 crossref_primary_10_1177_13524585241302174 crossref_primary_10_1007_s40120_023_00475_8 crossref_primary_10_1002_14651858_CD012186_pub2 crossref_primary_10_1007_s40120_019_00172_5 crossref_primary_10_1080_14737175_2023_2208347 crossref_primary_10_2147_PPA_S221882 crossref_primary_10_3389_fneur_2021_766956 crossref_primary_10_1111_ene_13692 crossref_primary_10_1007_s40271_020_00454_3 crossref_primary_10_1016_j_smim_2022_101630 crossref_primary_10_1177_1756286419833574 crossref_primary_10_1001_jamanetworkopen_2019_7093 crossref_primary_10_3390_bioengineering11080858 crossref_primary_10_1177_1352458520925369 crossref_primary_10_1016_j_neurol_2025_06_015 crossref_primary_10_1016_j_msard_2024_105881 crossref_primary_10_1016_j_neurol_2025_06_013 crossref_primary_10_1136_jnnp_2020_324869 crossref_primary_10_1080_14737167_2019_1635014 crossref_primary_10_3389_fpubh_2024_1494018 crossref_primary_10_1055_a_1351_8552 crossref_primary_10_1016_j_ebiom_2019_08_065 crossref_primary_10_1136_jnnp_2022_330533 crossref_primary_10_1186_s12883_020_01672_w crossref_primary_10_3390_cells9061396 crossref_primary_10_1111_ene_14790 crossref_primary_10_2147_DNND_S203406 crossref_primary_10_1007_s41669_022_00363_1 crossref_primary_10_1136_jnnp_2019_322480 crossref_primary_10_1016_j_msard_2024_105638 crossref_primary_10_1016_j_nicl_2021_102732 crossref_primary_10_3389_fimmu_2024_1441733 crossref_primary_10_1002_14651858_CD013874_pub3 crossref_primary_10_4049_jimmunol_2001130 crossref_primary_10_1016_j_msard_2020_102521 crossref_primary_10_3389_fneur_2021_667398 crossref_primary_10_1007_s00115_020_00906_z crossref_primary_10_1186_s12911_021_01479_w crossref_primary_10_1016_j_msard_2018_12_030 crossref_primary_10_1016_j_msard_2022_104185 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1177/1352458517751049 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1477-0970 |
| ExternalDocumentID | 29353550 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -TM .2E .2F .2G .2J .2N 01A 0R~ 123 18M 1~K 29M 31R 31S 31U 31X 31Y 31Z 36B 39C 3V. 4.4 53G 54M 5VS 7X7 88E 8FI 8FJ 8R4 8R5 AABMB AABOD AACKU AACMV AACTG AADTT AADUE AAEWN AAGGD AAGMC AAJIQ AAJOX AAJPV AAKGS AAMGE AANSI AAPEO AAQDB AAQXH AAQXI AARDL AARIX AATAA AATBZ AAUAS AAXOT AAYTG AAZBJ ABAFQ ABAWC ABAWP ABCCA ABCJG ABDWY ABEIX ABFWQ ABHFT ABHKI ABHQH ABJIS ABJNI ABKRH ABLUO ABNCE ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABUWG ABVFX ABVVC ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACFYK ACGBL ACGFO ACGFS ACGZU ACJER ACJTF ACLFY ACLHI ACLZU ACNXM ACOFE ACOXC ACPRK ACROE ACRPL ACSBE ACSIQ ACTQU ACUAV ACUIR ACXKE ACXMB ADBBV ADEIA ADMPF ADNBR ADNMO ADNON ADRRZ ADTBJ ADUCT ADUKL ADVBO ADYCS ADZYD ADZZY AECGH AECVZ AEDTQ AEKYL AENEX AEPTA AEQLS AERKM AESZF AEUHG AEUIJ AEWDL AEWHI AEXFG AEXNY AFEET AFKBI AFKRA AFKRG AFMOU AFQAA AFUIA AFVCE AFWMB AGHKR AGKLV AGNHF AGPXR AGWFA AGWNL AHDMH AHHFK AHMBA AIGRN AIOMO AJABX AJEFB AJMMQ AJSCY AJUZI AJXAJ AJXGE ALIPV ALKWR ALMA_UNASSIGNED_HOLDINGS ALTZF AMCVQ ANDLU ARTOV ASPBG AUTPY AVWKF AYAKG AZFZN AZQEC B3H B8M B8O B8R B8Z B93 B94 BBRGL BDDNI BENPR BKIIM BKNYI BKSCU BPACV BPHCQ BSEHC BVXVI BWJAD BYIEH CAG CBRKF CCPQU CDWPY CFDXU CGR COF CORYS CQQTX CS3 CUTAK CUY CVF DB0 DC- DC0 DD- DD0 DE- DF0 DO- DOPDO DU5 DV7 DV9 D~Y EBS ECM EIF EJD EMOBN ESX F5P FD6 FEDTE FHBDP FYUFA GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HMCUK HVGLF HZ~ J8X K.F K.J K9- M0R M1P M4V N9A NPM O9- P.B P2P PQQKQ PROAC PSQYO Q1R Q2X Q7K Q7L Q7R Q7U Q7X Q82 Q83 ROL S01 SAUOL SCNPE SDB SFB SFC SFK SFN SFT SGA SGO SGP SGR SGV SGX SGZ SHG SNB SPJ SPQ SPV SQCSI STM UKHRP XJT ZONMY ZPPRI ZRKOI ZSSAH 7X8 AAPII ABIDT ABJZC ADDLC ADEBD AJGYC AJHME AJVBE SASJQ |
| ID | FETCH-LOGICAL-c585t-748fd25e9a41f6b57df9c4b849e6f1b25d5a343ef9052c9a23fb98c2e0c927e62 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 368 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000429033400085&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1477-0970 |
| IngestDate | Sun Sep 28 11:40:17 EDT 2025 Wed Feb 19 02:31:39 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | GRADE methodology Multiple sclerosis disease-modifying therapies guideline |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c585t-748fd25e9a41f6b57df9c4b849e6f1b25d5a343ef9052c9a23fb98c2e0c927e62 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://journals.sagepub.com/doi/pdf/10.1177/1352458517751049 |
| PMID | 29353550 |
| PQID | 1989911725 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1989911725 pubmed_primary_29353550 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-02-01 |
| PublicationDateYYYYMMDD | 2018-02-01 |
| PublicationDate_xml | – month: 02 year: 2018 text: 2018-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Multiple sclerosis |
| PublicationTitleAlternate | Mult Scler |
| PublicationYear | 2018 |
| References | 32013769 - Mult Scler. 2020 Feb 4;:1352458520906383 |
| References_xml | – reference: 32013769 - Mult Scler. 2020 Feb 4;:1352458520906383 |
| SSID | ssj0007735 |
| Score | 2.6674774 |
| Snippet | Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 96 |
| SubjectTerms | Consensus Evidence-Based Medicine - standards Humans Immunologic Factors - administration & dosage Immunomodulation Multiple Sclerosis - drug therapy Practice Guidelines as Topic - standards |
| Title | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29353550 https://www.proquest.com/docview/1989911725 |
| Volume | 24 |
| WOSCitedRecordID | wos000429033400085&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeMhJrVMdx4nhCVdUCQ6MKipQtil9Sl6SQlt_POUnJhpBYMkSKHJ_v7M93n-5D6MEyp3xiuKe5bzzmW-LlkaVeYIkkWkBAaV2LTfAkidNUzNqEW9XSKjd7Yr1R61K5HPnAcXsgMDkNH5cfnlONctXVVkJjG_UCgDLOq3nadQvnvBbY9BnnHhGcdGXKgQ_Ag7mSGOfglewXgFkfNJPD__7iETpoISYeNj5xjLZMcYL2pm0R_RSl49H89WX6NhgPE_y0dn2u4D0uCwxgEC-7XtZu_fAPEx2XFjd8c-ySt3hDRcQVjAJn7aI6Q--T8Xz07LUCC56Cqa9cH1GraWhEDosUyZBrKxSTMRMmsr6koQ7zgAXGChJSJXIaWCliRQ1RgnIT0XO0U5SFuUSYG-0rKf1ICQCJcIdThikqg1hZmxti--h-Y7MMHNhVJfLClOsq66zWRxeN4bNl02kjAywSAiAiV3_4-hrtA5iJG0b1DepZCF9zi3bV12pRfd7VngHPZDb9BnYFw7c |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ECTRIMS%2FEAN+Guideline+on+the+pharmacological+treatment+of+people+with+multiple+sclerosis&rft.jtitle=Multiple+sclerosis&rft.au=Montalban%2C+Xavier&rft.au=Gold%2C+Ralf&rft.au=Thompson%2C+Alan+J&rft.au=Otero-Romero%2C+Susana&rft.date=2018-02-01&rft.eissn=1477-0970&rft.volume=24&rft.issue=2&rft.spage=96&rft_id=info:doi/10.1177%2F1352458517751049&rft_id=info%3Apmid%2F29353550&rft_id=info%3Apmid%2F29353550&rft.externalDocID=29353550 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-0970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-0970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-0970&client=summon |